Our data showed that the proportions of peripheral CD3–CD19+ B cells and AChR-ab levels were significantly increased in patients with MG exacerbations, suggesting that alterations in the levels of of CD3–CD19+ B cells and AChR-ab are more helpful in assessing GMG disease status (24, 25). The gene discussed is CD19; the disease is myasthenia gravis.